SCHEMBL5163545

SCHEMBL5163545

CC(C)Cn1cnc2c(N)nc(OCCc3ccccc3)nc21

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 13/20 0.52
ADORA2B P29275 7/20 0.52
ADORA1 P30542 7/20 0.52
ADORA3 P0DMS8 3/20 0.52
TLR7 Q9NYK1 3/20 0.50
PDE4D Q08499 2/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
HRH2 P25021 1/20 0.50
ADRA1D P25100 1/20 0.50
HTR2A P28223 1/20 0.50
ADRA1A P35348 1/20 0.50
NUDT1 P36639 1/20 0.50
HTR2B P41595 1/20 0.50
KCNH2 Q12809 1/20 0.50
TMIGD3 P0DMS9 4/20 0.48
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163883 0.94 ADORA2A (0.52) ADORA2AADORA2BADORA1ADORA3TLR7
SCHEMBL5162145 0.91 ADORA2A (0.50) ADORA2AADORA2BADORA1ADORA3PDE4D
SCHEMBL5161691 0.87 ADORA2A (0.63) ADORA2AADORA2BADORA1ADORA3TLR7
SCHEMBL5161857 0.86 ADORA2A (0.61) ADORA2AADORA2BADORA1ADORA3PDE4D
SCHEMBL5158576 0.86 ADORA2A (0.51) ADORA2AADORA2BADORA1ADORA3TLR7
SCHEMBL5162224 0.85 ADORA2A (0.64) ADORA2AADORA2BADORA1ADORA3TLR7
SCHEMBL5162367 0.82 ADORA2A (0.56) ADORA2AADORA2BADORA1ADORA3TLR7
SCHEMBL5160241 0.82 ADORA2A (0.56) ADORA2AADORA2BADORA1ADORA3TLR7
SCHEMBL5163585 0.82 ADORA2A (0.52) ADORA2AADORA2BADORA1ADORA3PDE4D
SCHEMBL5164645 0.82 ADORA2A (0.52) ADORA2AADORA2BADORA1ADORA3PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189730-B2 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-03-13 US disclosed
EP-1456209-B1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2007-02-28 EP disclosed
EP-1456209-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2004-09-15 EP disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 US disclosed
WO-2003051882-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 ADORA2A 1/4885ADORA2B 2/4885ADORA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.